X
ALLO icon

Xponance’s Allogene Therapeutics ALLO Stock Holding History

Xponance’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.6K Buy
25,312
+11,640
+85% +$25.6K ﹤0.01% 1782
2026
Q1 		$33.4K Buy
13,672
+1,867
+16% +$3.74K ﹤0.01% 1652
2025
Q4 		$16.2K Hold
11,805
– – ﹤0.01% 1563
2025
Q3 		$14.6K Hold
11,805
– – ﹤0.01% 1525
2025
Q2 		$13.3K Buy
+11,805
New +$15.7K ﹤0.01% 1505

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Xponance's ALLO Position: Q2 2026 in Review

Xponance increased its Allogene Therapeutics (ALLO) stake by 85% in Q2 2026, buying an estimated $25.6K and bringing the position to 25,312 shares worth $52.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1782.

Xponance first reported a position in ALLO in Q2 2025 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Xponance held 25,312 shares of Allogene Therapeutics worth $52.6K as of Q2 2026.
  • Xponance bought 11,640 Allogene Therapeutics shares in Q2 2026, an estimated $25.6K.
  • Allogene Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1782 holding.
  • Xponance first reported a position in Allogene Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.